This article is more than 5 years old. Information may no longer be current.
Lymphoma & Myeloma 2015 provided ‘comprehensive’ overview of lymphatic, plasma cell malignancies
Click Here to Manage Email Alerts
NEW YORK — World-renowned experts in the fields of multiple myeloma, chronic lymphocytic leukemia and lymphoma provided attendees of Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies with the latest updates and guidelines for enhancing diagnostic, prognostic and therapeutic algorithms.
Lymphoma & Myeloma — chaired by Morton Coleman, MD, John P. Leonard, MD, Ruben Niesvizky, MD, and Richard R. Furman, MD, all of whom are faculty members from Weill Cornell Medicine — has been the premier forum on the latest advances in lymphoma, chronic lymphocytic leukemia, myeloma and other plasma cell neoplasms for the last 15 years.
“Imedex is proud to partner with the congress chairmen in bringing this successful, independent, medical educational congress to the hematology oncology health care community. The Lymphoma & Myeloma Congress is dedicated to improving patient lives by providing the latest in high quality education to physicians and allied health care providers,” said Andrew Schutt, CEO of Imedex LLC, the congress organizer and accredited provider.
HemOnc Today served as an official media partner for this year’s congress.
Over 3 days, the congress hosted delegates from 44 countries, with more than 750 health care practitioners interested and/or involved in the treatment of patients with hematologic malignancies. Faculty and audience dialogue was encouraged through meet-the-expert sessions, product theaters and expert-led panel discussions spread throughout the meeting.
Current clinical challenges and considerations for the treatment and management of patients with multiple myeloma were prominently discussed, including debates on the use of histone acetyltransferases and histone deacetylases, the necessity of stem cell transplant, and whether maintenance is required and, if so, the optimal approach.
Sessions in chronic lymphocytic leukemia updated the attendees on approved tyrosine kinase inhibitors, provided insight into the optimal utilization of standard-of-care therapies, discussed assessment of risk, and highlighted novel therapeutic strategies with promise that are currently under clinical evaluation.
Presentations in lymphoma allowed the attendees to evaluate optimal therapeutic strategies for patients with diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, Hodgkin’s lymphoma and peripheral T-cell lymphoma. Included within these lectures and debates were discussion for patient selection, management of disease- and therapy-related adverse events, and how to proceed after therapy failure.
Additionally, presentations in the basic science sessions discussed novel biomarkers for disease prognosis, along with novel molecular pathways for targeted therapy.
“This congress represents the largest and most comprehensive of its kind in America. Anyone attending this meeting left with a full knowledge of what is the latest and most relevant topics in lymphatic and plasma cell malignancies as imparted by the best in medicine,” said Coleman, director of the Center for Lymphoma and Myeloma at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, a clinical professor of medicine at Weill Cornell Medical College, and chairman of Lymphoma & Myeloma.
Of special note, David Roodman MD, PhD, received the Joseph Michaeli Award for Contributions to Myeloma Research, and Randy Gascoyne, MD, FRCPC, received the John Ultmann Award for Contributions to Lymphoma Research.
Organized by Imedex LLC, this accredited CME meeting will be held again Oct. 13-15, 2016, at the Waldorf Astoria Hotel. Registration is open and abstracts will be accepted.